DEXCOM INC — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that DEXCOM INC filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2017 | Dec 31, 2017 | $221.00M | Feb 27, 2018 |
| FY2017 | Sep 30, 2017 | $184.60M | Feb 27, 2018 |
| FY2017 | Jun 30, 2017 | $170.60M | Feb 27, 2018 |
| FY2017 | Mar 31, 2017 | $142.30M | Feb 27, 2018 |
| FY2017 | Dec 31, 2016 | $171.20M | Feb 27, 2018 |
| FY2017 | Sep 30, 2016 | $148.60M | Feb 27, 2018 |
| FY2017 | Jun 30, 2016 | $137.30M | Feb 27, 2018 |
| FY2017 | Mar 31, 2016 | $116.20M | Feb 27, 2018 |
| FY2016 | Dec 31, 2015 | $130.80M | Feb 28, 2017 |
| FY2016 | Sep 30, 2015 | $105.20M | Feb 28, 2017 |
Revenue
Revenue recognized from contracts with customers under ASC 606, excluding taxes collected on behalf of government authorities. This is the primary revenue concept for many companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $4.66B | Feb 12, 2026 |
| FY2025 | Dec 31, 2024 | $4.03B | Feb 12, 2026 |
| FY2025 | Dec 31, 2023 | $3.62B | Feb 12, 2026 |
| FY2024 | Dec 31, 2022 | $2.91B | Feb 18, 2025 |
| FY2023 | Dec 31, 2021 | $2.45B | Feb 8, 2024 |
| FY2022 | Dec 31, 2020 | $1.93B | Feb 9, 2023 |
| FY2019 | Dec 31, 2019 | $462.80M | Feb 13, 2020 |
| FY2019 | Sep 30, 2019 | $396.30M | Feb 13, 2020 |
| FY2019 | Jun 30, 2019 | $336.40M | Feb 13, 2020 |
| FY2019 | Mar 31, 2019 | $280.50M | Feb 13, 2020 |
Revenue (Net Sales)
Net sales revenue — gross revenue less returns, allowances, and discounts. Used by many manufacturers and retailers as the primary top-line figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2017 | Dec 31, 2017 | $718.50M | Feb 27, 2018 |
| FY2017 | Dec 31, 2016 | $573.30M | Feb 27, 2018 |
| FY2017 | Dec 31, 2015 | $402.00M | Feb 27, 2018 |
| FY2016 | Dec 31, 2014 | $259.20M | Feb 28, 2017 |
| FY2015 | Dec 31, 2013 | $160.00M | Feb 23, 2016 |
| FY2014 | Dec 31, 2012 | $99.90M | Feb 25, 2015 |
Gross Profit
Revenue minus the cost of goods sold (COGS). Gross profit shows how much revenue remains to cover operating expenses, R&D, and administrative costs before calculating operating income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $2.80B | Feb 12, 2026 |
| FY2025 | Dec 31, 2024 | $2.44B | Feb 12, 2026 |
| FY2025 | Dec 31, 2023 | $2.29B | Feb 12, 2026 |
| FY2024 | Dec 31, 2022 | $1.88B | Feb 18, 2025 |
| FY2023 | Dec 31, 2021 | $1.68B | Feb 8, 2024 |
| FY2022 | Dec 31, 2020 | $1.28B | Feb 9, 2023 |
| FY2019 | Dec 31, 2019 | $309.30M | Feb 13, 2020 |
| FY2019 | Sep 30, 2019 | $246.90M | Feb 13, 2020 |
| FY2019 | Jun 30, 2019 | $206.50M | Feb 13, 2020 |
| FY2019 | Mar 31, 2019 | $168.80M | Feb 13, 2020 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $836.30M | Feb 12, 2026 |
| FY2025 | Dec 31, 2024 | $576.20M | Feb 12, 2026 |
| FY2025 | Dec 31, 2023 | $541.50M | Feb 12, 2026 |
| FY2024 | Dec 31, 2022 | $341.20M | Feb 18, 2025 |
| FY2023 | Dec 31, 2021 | $216.90M | Feb 8, 2024 |
| FY2022 | Dec 31, 2020 | $549.70M | Feb 9, 2023 |
| FY2019 | Dec 31, 2019 | $92.70M | Feb 13, 2020 |
| FY2019 | Sep 30, 2019 | $45.80M | Feb 13, 2020 |
| FY2019 | Jun 30, 2019 | ($10.50M) | Feb 13, 2020 |
| FY2019 | Mar 31, 2019 | ($26.90M) | Feb 13, 2020 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $911.80M | Feb 12, 2026 |
| FY2025 | Dec 31, 2024 | $600.00M | Feb 12, 2026 |
| FY2025 | Dec 31, 2023 | $597.70M | Feb 12, 2026 |
| FY2024 | Dec 31, 2022 | $391.20M | Feb 18, 2025 |
| FY2023 | Dec 31, 2021 | $265.80M | Feb 8, 2024 |
| FY2022 | Dec 31, 2020 | $299.50M | Feb 9, 2023 |
| FY2021 | Dec 31, 2019 | $142.30M | Feb 14, 2022 |
| FY2020 | Dec 31, 2018 | ($186.30M) | Feb 11, 2021 |
| FY2019 | Dec 31, 2017 | ($42.50M) | Feb 13, 2020 |
| FY2018 | Dec 31, 2016 | ($63.90M) | Feb 21, 2019 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $599.10M | Feb 12, 2026 |
| FY2025 | Dec 31, 2024 | $552.40M | Feb 12, 2026 |
| FY2025 | Dec 31, 2023 | $505.80M | Feb 12, 2026 |
| FY2024 | Dec 31, 2022 | $484.20M | Feb 18, 2025 |
| FY2023 | Dec 31, 2021 | $517.10M | Feb 8, 2024 |
| FY2022 | Dec 31, 2020 | $359.90M | Feb 9, 2023 |
| FY2021 | Dec 31, 2019 | $273.50M | Feb 14, 2022 |
| FY2020 | Dec 31, 2018 | $199.70M | Feb 11, 2021 |
| FY2019 | Dec 31, 2017 | $185.40M | Feb 13, 2020 |
| FY2018 | Dec 31, 2016 | $156.10M | Feb 21, 2019 |
SG&A Expense
Selling, general, and administrative expenses — the overhead costs of running the business, including salaries, marketing, legal fees, and corporate office costs. Excludes COGS and R&D.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.29B | Feb 12, 2026 |
| FY2025 | Dec 31, 2024 | $1.29B | Feb 12, 2026 |
| FY2025 | Dec 31, 2023 | $1.19B | Feb 12, 2026 |
| FY2024 | Dec 31, 2022 | $1.01B | Feb 18, 2025 |
| FY2023 | Dec 31, 2021 | $810.50M | Feb 8, 2024 |
| FY2022 | Dec 31, 2020 | $618.20M | Feb 9, 2023 |
| FY2021 | Dec 31, 2019 | $515.70M | Feb 14, 2022 |
| FY2020 | Dec 31, 2018 | $432.80M | Feb 11, 2021 |
| FY2019 | Dec 31, 2017 | $349.20M | Feb 13, 2020 |
| FY2018 | Dec 31, 2016 | $286.20M | Feb 21, 2019 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.44B | Feb 12, 2026 |
| FY2025 | Dec 31, 2024 | $989.50M | Feb 12, 2026 |
| FY2025 | Dec 31, 2023 | $748.50M | Feb 12, 2026 |
| FY2024 | Dec 31, 2022 | $669.50M | Feb 18, 2025 |
| FY2023 | Dec 31, 2021 | $442.50M | Feb 8, 2024 |
| FY2022 | Dec 31, 2020 | $475.60M | Feb 9, 2023 |
| FY2021 | Dec 31, 2019 | $314.50M | Feb 14, 2022 |
| FY2020 | Dec 31, 2018 | $123.20M | Feb 11, 2021 |
| FY2019 | Dec 31, 2017 | $92.00M | Feb 13, 2020 |
| FY2018 | Dec 31, 2016 | $56.20M | Feb 21, 2019 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $363.50M | Feb 12, 2026 |
| FY2025 | Dec 31, 2024 | $358.80M | Feb 12, 2026 |
| FY2025 | Dec 31, 2023 | $236.60M | Feb 12, 2026 |
| FY2024 | Dec 31, 2022 | $364.80M | Feb 18, 2025 |
| FY2023 | Dec 31, 2021 | $389.20M | Feb 8, 2024 |
| FY2022 | Dec 31, 2020 | $199.00M | Feb 9, 2023 |
| FY2021 | Dec 31, 2019 | $180.00M | Feb 14, 2022 |
| FY2020 | Dec 31, 2018 | $67.10M | Feb 11, 2021 |
| FY2019 | Dec 31, 2017 | $66.00M | Feb 13, 2020 |
| FY2018 | Dec 31, 2016 | $55.70M | Feb 21, 2019 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $6.34B | Feb 12, 2026 |
| FY2025 | Dec 31, 2024 | $6.48B | Feb 12, 2026 |
| FY2024 | Dec 31, 2023 | $6.26B | Feb 18, 2025 |
| FY2023 | Dec 31, 2022 | $5.39B | Feb 8, 2024 |
| FY2022 | Dec 31, 2021 | $4.93B | Feb 9, 2023 |
| FY2021 | Dec 31, 2020 | $4.29B | Feb 14, 2022 |
| FY2020 | Dec 31, 2019 | $2.40B | Feb 11, 2021 |
| FY2019 | Dec 31, 2018 | $1.92B | Feb 13, 2020 |
| FY2018 | Dec 31, 2017 | $904.10M | Feb 21, 2019 |
| FY2017 | Dec 31, 2016 | $402.80M | Feb 27, 2018 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $3.59B | Feb 12, 2026 |
| FY2025 | Dec 31, 2024 | $4.38B | Feb 12, 2026 |
| FY2024 | Dec 31, 2023 | $4.20B | Feb 18, 2025 |
| FY2023 | Dec 31, 2022 | $3.26B | Feb 8, 2024 |
| FY2022 | Dec 31, 2021 | $2.89B | Feb 9, 2023 |
| FY2021 | Dec 31, 2020 | $2.46B | Feb 14, 2022 |
| FY2020 | Dec 31, 2019 | $1.51B | Feb 11, 2021 |
| FY2019 | Dec 31, 2018 | $1.25B | Feb 13, 2020 |
| FY2018 | Dec 31, 2017 | $484.70M | Feb 21, 2019 |
| FY2017 | Dec 31, 2016 | $119.00M | Feb 27, 2018 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $2.75B | Feb 12, 2026 |
| FY2025 | Dec 31, 2024 | $2.10B | Feb 12, 2026 |
| FY2025 | Dec 31, 2023 | $2.07B | Feb 12, 2026 |
| FY2025 | Dec 31, 2022 | $2.13B | Feb 12, 2026 |
| FY2024 | Dec 31, 2021 | $2.04B | Feb 18, 2025 |
| FY2023 | Dec 31, 2020 | $1.55B | Feb 8, 2024 |
| FY2022 | Dec 31, 2019 | $882.60M | Feb 9, 2023 |
| FY2021 | Dec 31, 2018 | $663.30M | Feb 14, 2022 |
Goodwill
An intangible asset representing the premium paid above fair value when acquiring another company. A large goodwill balance signals a history of acquisitions at premium prices.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $24.20M | Feb 12, 2026 |
| FY2025 | Dec 31, 2024 | $22.80M | Feb 12, 2026 |
| FY2024 | Dec 31, 2023 | $25.20M | Feb 18, 2025 |
| FY2023 | Dec 31, 2022 | $25.70M | Feb 8, 2024 |
| FY2022 | Dec 31, 2021 | $26.50M | Feb 9, 2023 |
| FY2021 | Dec 31, 2020 | $19.30M | Feb 14, 2022 |
| FY2020 | Dec 31, 2019 | $18.60M | Feb 11, 2021 |
| FY2019 | Dec 31, 2018 | $18.70M | Feb 13, 2020 |
| FY2018 | Dec 31, 2017 | $12.10M | Feb 21, 2019 |
| FY2017 | Dec 31, 2016 | $11.30M | Feb 27, 2018 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $2.43B | Feb 12, 2026 |
| FY2025 | Dec 31, 2024 | $1.60B | Feb 12, 2026 |
| FY2024 | Dec 31, 2023 | $1.02B | Feb 18, 2025 |
| FY2023 | Dec 31, 2022 | $479.90M | Feb 8, 2024 |
| FY2022 | Dec 31, 2021 | $138.70M | Feb 9, 2023 |
| FY2022 | Dec 31, 2020 | ($78.20M) | Feb 9, 2023 |
| FY2020 | Dec 31, 2019 | ($695.70M) | Feb 11, 2021 |
| FY2019 | Dec 31, 2018 | ($798.90M) | Feb 13, 2020 |
| FY2018 | Dec 31, 2017 | ($671.80M) | Feb 21, 2019 |
| FY2017 | Dec 31, 2016 | ($621.00M) | Feb 27, 2018 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $917.70M | Feb 12, 2026 |
| FY2025 | Dec 31, 2024 | $606.10M | Feb 12, 2026 |
| FY2025 | Dec 31, 2023 | $566.30M | Feb 12, 2026 |
| FY2024 | Dec 31, 2022 | $642.30M | Feb 18, 2025 |
| FY2023 | Dec 31, 2021 | $1.05B | Feb 8, 2024 |
| FY2022 | Dec 31, 2020 | $817.60M | Feb 9, 2023 |
| FY2021 | Dec 31, 2019 | $446.20M | Feb 14, 2022 |
| FY2020 | Dec 31, 2018 | $1.14B | Feb 11, 2021 |
| FY2019 | Dec 31, 2017 | $441.50M | Feb 13, 2020 |
| FY2018 | Dec 31, 2016 | $94.50M | Feb 21, 2019 |
Long-Term Debt
Debt obligations due more than one year from the balance sheet date — bonds, term loans, and notes payable. High long-term debt relative to equity can signal elevated financial leverage.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2014 | Dec 31, 2014 | $4.60M | Feb 25, 2015 |
| FY2013 | Dec 31, 2013 | $6.80M | Feb 20, 2014 |
| FY2012 | Dec 31, 2012 | $7.00M | Feb 21, 2013 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 2 | Feb 12, 2026 |
| FY2025 | Dec 31, 2024 | 1 | Feb 12, 2026 |
| FY2025 | Dec 31, 2023 | 1 | Feb 12, 2026 |
| FY2024 | Dec 31, 2022 | 0 | Feb 18, 2025 |
| FY2023 | Dec 31, 2021 | 0 | Feb 8, 2024 |
| FY2022 | Dec 31, 2020 | 1 | Feb 9, 2023 |
| FY2019 | Dec 31, 2019 | 1 | Feb 13, 2020 |
| FY2019 | Sep 30, 2019 | 0 | Feb 13, 2020 |
| FY2019 | Jun 30, 2019 | 0 | Feb 13, 2020 |
| FY2019 | Mar 31, 2019 | 0 | Feb 13, 2020 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 2 | Feb 12, 2026 |
| FY2025 | Dec 31, 2024 | 1 | Feb 12, 2026 |
| FY2025 | Dec 31, 2023 | 1 | Feb 12, 2026 |
| FY2024 | Dec 31, 2022 | 0 | Feb 18, 2025 |
| FY2023 | Dec 31, 2021 | 0 | Feb 8, 2024 |
| FY2022 | Dec 31, 2020 | 1 | Feb 9, 2023 |
| FY2019 | Dec 31, 2019 | 1 | Feb 13, 2020 |
| FY2019 | Sep 30, 2019 | 0 | Feb 13, 2020 |
| FY2019 | Jun 30, 2019 | 0 | Feb 13, 2020 |
| FY2019 | Mar 31, 2019 | 0 | Feb 13, 2020 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 384.80M | Feb 12, 2026 |
| FY2025 | Dec 31, 2024 | 390.70M | Feb 12, 2026 |
| FY2024 | Dec 31, 2023 | 385.40M | Feb 18, 2025 |
| FY2023 | Dec 31, 2022 | 386.30M | Feb 8, 2024 |
| FY2022 | Dec 31, 2021 | 388.00M | Feb 9, 2023 |
| FY2021 | Dec 31, 2020 | 96.10M | Feb 14, 2022 |
| FY2020 | Dec 31, 2019 | 91.60M | Feb 11, 2021 |
| FY2019 | Dec 31, 2018 | 90.00M | Feb 13, 2020 |
| FY2018 | Dec 31, 2017 | 87.00M | Feb 21, 2019 |
| FY2017 | Dec 31, 2016 | 84.60M | Feb 27, 2018 |